目的：探讨阿托伐他汀钙片联合沙库巴曲缬沙坦钠片对慢性心力衰竭患者临床疗效、心脏彩超指标、血清指标的影响。方法：按随机数字表法将湖南省长沙市三真康复医院2022年1月至2022年12月收治的87例慢性心力衰竭患者分为对照组（采用阿托伐他汀钙片口服及利尿等治疗）43例与观察组（在对照组的基础上联合沙库巴曲缬沙坦钠片口服治疗）44例。比较两组患者治疗后临床疗效及再入院率,治疗前后心脏彩超与血清指标,治疗期间不良反应发生情况。结果：治疗2个月后观察组患者临床总有效率为95.45%,显著高于对照组的74.42%;不良反应总发生率与再入院率均显著低于对照组;与治疗前比,治疗后两组患者左室射血分数（LVEF）、收缩期峰流速（SPV）、左前降支舒张期峰流速（DPV）、时间速度积分（TVI）均显著升高,且观察组显著高于对照组,差异有统计学意义;观察组患者左室收缩期末期内径（LVESD）、左室舒张末期内径（LVEDD）显著缩短,且观察组显著短于对照组;治疗前后对照组患者LVEDD组内比较,差异无统计学差异（P>0.05）。结论：采用阿托伐他汀钙片联合沙库巴曲缬沙坦钠片治疗,对改善慢性心力衰竭患者预后及提高其生活质量有明显促进作用。

Objective The aim of this report is to explore the effects of atorvastatin calcium tablets combined with sacubitril/valsartan on clinical efficacy, cardiac color ultrasound indexes and serum indexes in patients with chronic heart failure. Methods We collected data of 87 patients with chronic heart failure admitted to Sanzhen Rehabilitation Hospital in Changsha, Hunan Province from January 2022 to December 2022. According to the random number table method, the patients were divided into control group (treated with atorvastatin calcium tablets orally and diuretics, etc. ) with 43 cases and observation group (treated with sacubitril/valsartan plus the same therapy as the control group) with 44 cases. Results were compared between the two groups, including post-therapy efficacy and readmission rates, cardiac ultrasound and serum indexes before and after treatment, and the occurrence of adverse reactions during treatment. Results After 2 months of treatment, the total clinical efficiency of the observation group was 95.45%, which was significantly higher than that of the control group (74.42%). And the overall incidence of adverse reactions and the readmission rate of the observation group were observably lower than those of the control group. Compared with the pre-therapy period, an increase of various indicators was significantly obvious in both groups after treatment, including left ventricular ejection fraction (LVEF), systolic peak velocity (SPV), left anterior descending branch diastolic peak velocity (DPV) and time velocity integral (TVI). And the changes in the observation group were signally more obvious than the control group, with statistically significant differences between the two groups. Both of the two groups had an evident decrease in the left ventricular end-systolic diameter (LVESD) and the left ventricular end-diastolic diameter (LVEDD). And the LVESD and LVEDD were lower in the observation group than in the control group. However, there was no statistically significant difference in LVEDD level through the intra-group comparison of the control group before and after treatment. Conclusion Atorvastatin calcium tablets combined with sacubitril/valsartan has a good application effect in patients with chronic heart failure, as it apparently contributes to improving the prognosis and enhancing the quality of their lives.